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Abstract
Background: We recently isolated and identified Zizimin2 as a functional factor that is highly expressed in murine
splenic germinal center B cells after immunization with T-cell-dependent antigen. Zizimin2 was revealed to be a
new family member of Dock (dedicator of cytokinesis), Dock11, which is the guanine nucleotide exchange factor
for Cdc42, a low-molecular-weight GTPase. However, the molecular function of Zizimin2 in acquired immunity has
not been elucidated.
Results: In this study, we show that the protein expression of Zizimin2, which is also restricted to lymphoid tissues
and lymphocytes, is reduced in aged mice. Over-expression of full-length Zizimin2 induced filopodial formation in
293T cells, whereas expression of CZH2 domain inhibited it. Stimulation of Fcg receptor and Toll-like receptor 4
triggered Zizimin2 up-regulation and Cdc42 activation in bone marrow-derived dendritic cells.
Conclusions: These data suggest that Zizimin2 is an immune-related and age-regulated guanine nucleotide
exchange factor, which facilitates filopodial formation through activation of Cdc42, which results in activation of
cell migration.
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Background
Zizimin2, also called Dock11 (dedicator of cytokinesis 11),
has been reported as one of the human Dock180 super-
family proteins [1]. We recently identified Zizimin2 as a
238-kDa protein that is highly expressed in germinal cen-
ter B lymphocytes after T-cell-dependent antigen immuni-
zation [2]. The expression of this gene is regulated in
lymphocytes and organs, such as spleen, thymus, and
lymph nodes [2,3]. It has been shown that Zizimin2 binds
and activates nucleotide-free Cdc42 via its CZH2 [CDM
(ced5/DOCK180/myoblast city)-Zizimin homology 2]
domain [4] and mediates positive feedback on the active
form, GTP-bound Cdc42 [5]. Cdc42, one of the well-
known Rho family members, regulates signaling pathways
that control diverse cellular functions including morphol-
ogy, migration, endocytosis, and cell cycle progression
[6-8]. These reports suggest that Zizimin2 has a role in
regulating the pathway downstream of Cdc42, leading to
cellular functions.
Cdc42 affects the formation of highly dynamic finger-
like actin-rich protrusions known as filopodia. Filopodia
contain parallel bundles of filamentous F-actin, and are
thought to be important for sensing the environment, for
example, guidance toward chemoattractants [9,10]. Cdc42
induces filopodia and lamellipodia in activated B cells [11].
Microinjection of constitutively active Cdc42 stimulates
filopodial extension in immature dendritic cells [12].
Another isoform of Zizimin subfamily, Zizimin1 (Dock9)
is also known to be capable to interact with Cdc42
through the CZH2 domain, and this interaction induces
the formation of filopodia in NIH-3T3 cells expressing
exogenous murine Zizimin1, although their tissue distribu-
tion is remarkably different [2,13]. DOCK2-deficient plas-
macytoid dendritic cells (pDCs) failed to migrate into the
periarteriolar lymphoid sheaths of the spleen [14]. In
DOCK-deficient pDCs, chemokine-induced Rac activation
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lity and the loss of polarity during chemotaxis [14].
Although upstream effectors for Cdc42, which activates
the pathway to filopodial formation, especially receptors
located in plasma membrane, have not been identified yet,
Fc receptor and Toll-like receptor (TLR) are candidates
for the receptors because they are involved in many
immune responses. Fc receptor is a protein found on the
surface of certain cells, including natural killer cells,
macrophages, neutrophils, dendritic cells, and mast cells,
and contributes to the protective functions of not only the
innate but also acquired immune system. There are several
different types of Fc receptor, which are classified on the
basis of the type of antibody that they recognize. For
example, Fcg receptors (FcgR) recognize IgG. They interact
with an IgG-coated antigen so they are involved in
acquired immunity [15]. TLR belongs to the family of pat-
tern recognition receptors that are used to recognize
microbial products from several classes of microbes, as
well as endogenous ligands. TLR4 is a receptor for gram-
negative lipopolysaccharide (LPS), respiratory syncytial
virus protein F, and other endogenous ligands, such as
surfactant protein A and fibronectin fragment [16].
These findings led us to clarify Zizimin2 function
regarding the signaling pathway leading to cell migration.
In this study, we show that Zizimin2 facilitates filopodial
formation via activation of Cdc42 as a downstream effec-
tor of Fcg receptor or TLR4 in bone marrow-derived den-
dritic cells (BMDC) and that Zizimin2 CZH2 domain has
dominant negative effects on cell migration.
Results
Zizimin2 is expressed in lymphoid organs
Since Zizimin2 was identified as a gene that is highly
expressed in murine splenic germinal center B cells after
immunization with T-cell-dependent antigen, and we
recently developed rat monoclonal anti-mouse Zizimin2
antibody [3], we first confirmed the expression level of
Zizimin2 protein in murine tissues. Western blot showed
that Zizimin2 is highly expressed in the lymphoid organs
such as thymus, spleen, lymph node (Figure 1A), splenic B
cells, T cells, myeloid DCs, and pDCs (Figure 1B). An
equal amount of protein loading was confirmed by pomso
staining of the membrane (Additional file 1: Figure S1).
Zizimin2 is down-regulated in aged mice
A correlational evidences between aging and immunose-
nescence has been intensively debated for a decade
[17-19], but the detailed mechanism of immunosenes-
cence has not been revealed yet. Therefore, the issue of
the expression of Zizimin2 being regulated in an age-
dependent manner has been our fllowing prominent inter-
est. Quantitative RT-PCR analysis shows that Zizimin2
gene is distinctly down-regulated in aged mouse spleen
(Figure 2A). Moreover, the expression level of Zizimin2
protein in aged mouse spleen was less than that in young
mouse spleen (7-8 weeks old); on the other hand, the
expression level of Zizimin1 in lung was stable, suggesting
that Zizimin2 expression is saliently regulated in age-
dependent manner in mouse spleen (Figure 2B, C).
Induction of filopodia
It has been shown that Cdc42 is a signal transducer in
the pathway leading to the induction of filopodial for-
mation [9] and Zizimin2 interacts with and activates
Cdc42 [2]. Therefore, it is speculated that over-expres-
sion of Zizimin2 induces filopodial formation. In order
to confirm this, Cdc42 or Zizimin2 was over-expressed
in 293T cells followed by immunofluorescence micro-
scopy. Over-expression of Cdc42WT and its active form
(Cdc42V12) in 293T cells induced filopodia, whereas the
negative form (Cdc42N17) did not inhibit them, sug-
gesting that Cdc42 is a positive regulator of filopodial
formation (Additional file 2: Figure S2). Over-expression
Figure 1 Expression profile of Zizimin1 and Zizimin2 protein.
A) Western blot analysis shows the expression levels of Zizimin1
and Zizimin2 in murine tissues described at the top of the panels.
a-Tubulin was used as a loading control. B) Western blot analysis of
Zizimin2 was carried out with cell extracts from splenic B cells,
splenic T cells, and pDC or mDC from bone marrow. a-Tubulin was
used as a loading control.
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domain prevented this induction, suggesting that Zizi-
min2 is also a positive regulator of filopodial formation,
which plays important physiological roles in guidance
toward chemoattraction (Figure 3) [10].
Zizimin2 is activated through Fcg receptor II/III or TLR4
signaling pathway
We reported that Zizimin2 binds and activates nucleo-
tide-free Cdc42 via its CZH2 domain [2]. To gain further
insight into the intracellular signaling of Zizimin2, we
Figure 2 Zizimin2, Zizimin1, and Zizimin3 expression in young and aged mice. A) Total RNA was prepared from young (7-8 weeks old)
or aged (24 months old) mice, followed by reverse transcription to obtain the cDNA. Quantitative RT-PCR was carried out with specific
primer sets for Zizimin2 and G3PDH. Relative mRNA levels were calculated using the delta-delta CT method using G3PDH as a housekeeping
gene. Asterisks indicate that the sample group is significantly different from aged mice at *** P < 0.0001 by Student’s t-test. Means ± S.D.
values of four experiments are presented. B) Lysates were prepared from three individual three young (7-8 weeks old) or aged (24 months
old) mouse tissues, which are described to the left of each panel, followed by western blotting. a-Tubulin was used as a loading control. C)
Expression levels of Zizimin2 and Zizimin1 were quantified as relative levels. Means ± S.D. values of three experiments are presented. ** P <
0.01 by Student’s t-test.
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from those which signaling is important for the immune
response of dendritic cells [16,20,21], are associated with
Zizimin2 or Cdc42. Stimulation of BMDC with anti-Fcg
receptor II/III or LPS, which is a TLR4 ligand, induced
Zizimin2 up-regulation and Cdc42 activation, which was
i n d i c a t e db ya ni n c r e a s ei nt h er a t i oo fG T P - b o u n d
Cdc42 versus total Cdc42 (Figure 4A, B). On the other
hand, CD40 did not affect Zizimin2 expression, therefore,
Zizimin2 does not seem to play a role in the CD40 sig-
naling pathway (Figure 4A).
We further investigated whether activation of the Fcg
receptor II/III or TLR4 induced filopodia. The stimulated
BMDC with anti-Fcg receptor II/III or LPS induced filo-
podia, which were shown by protrusions stained with
phalloidin (green) and partially merged with Zizimin2
expression sites (magenta), shown as white regions, and
up-regulation of Zizimin2 expression (Figure 4C). These
results suggest that Cdc42 and Zizimin2 play roles in filo-
podial formation as signal transducers from Fcg receptor
II/III and TLR4 in dendritic cells.
Discussion
Tissue distribution of Zizimin subfamily
According to their sequence similarity, Zizimin subfamily
includes three genes named Zizimin1/DOCK9, Zizimin2/
DOCK11 and Zizimin3/DOCK10 [1,13]. Zizimin2 is
expressed predominantly in hematopoietic tissues, espe-
cially, lymphoid organs for both acquired and innate
immune resoponse. Zizimin1 is predominantly involved in
non-hematopoietic tissues (Figure 1A), and Zizimin3 is
expressed in human peripheral blood B lymphocytes
involved in IL-4 signaling pathway [22]. Taken together
the specificity of Zizimin family, we suggest that Zizimin2
engages in mouse immune-system-specific signaling
pathway.
Age dependence of Zizimin2 expression
The expression level of Zizimin2 decreased in aged mice
compared with that in young mice, (Figure 2A-C), which
strongly suggests that the expression of Zizimin2 might
be regulated by an age-dependent mechanism. The
decreased expression might contribute to physiological
defects that are seen in the aged body, especially related
to immunosenescence.
Function of CZH2 domain
We examined and revealed that CZH2 domain of Zizi-
min2 inhibited filopodial formation followed by cell migra-
tion, which indicated that the CZH2 domain possesses
dominant negative effects on cell migration (Figure 3). It is
speculated that the CZH2 domain in Zizimin1 is inevitable
Figure 3 Over-expression of Zizimin2 induced filopodial formation. 293 T cells transfected with empty vector, or expression vectors with
full-length Zizimin2 or its CZH2 domain (CZH2) were stained with DAPI (DAPI), phalloidin (phalloidin), and anti-Zizimin2 antibody (Zizimin2)
followed by immunofluorescence microscopy. Right panels are merged images of phalloidin-stained and anti-Zizimin2-stained images. White
bars are 10 μm.
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7cells/ml of BMDC without or with stimulation by 1 μg/ml anti-IgG
Fab’2 for 2 min (left panel, anti-FcgRII/III), 1 μg/ml LPS for 5 min (middle panel), or 1 μg/ml anti-CD40 for 3 min (right panel) were lysed and
subjected to western blotting. a-Tubulin was used as a loading control. B) Cdc42 activation in response to stimulations. 10
7cells/ml of BMDC
were stimulated with 1 μg/ml anti-IgG Fab’2 for 0 to 10 min (left panel, anti-FcgRII/III) or 1 μg/ml LPS for 0 to 30 min (right panel) and subjected
to Cdc42 activation assay. Activated Cdc42 was assayed by precipitating GTP-loaded Cdc42 with bead-bound GST-PAK1-PBD, and detection of
Cdc42 in pull downs (upper panel) or total cell lysates (lower panel) by western blotting with anti-Cdc42. C) Filopodial formation in BMDC.
BMDC without or with stimulation by 1 μg/ml anti-IgG Fab’2 for 5 min (anti-FcgR) or 1 μg/ml LPS for 5 min were stained with phalloidin, which
was bound with F-actin (left panel, green), anti-mouse-Zizimin2 antibody, and anti-rat-IgG-Cy3-conjugated antibody (middle panel, magenta)
followed by immunofluorescence microscopy. Right panels are merged images of detected phalloidin (Alexa488) and detected Zizimin2 (Cy3).
White bars are 100 μm.
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[23,24]. In cases where Cdc42 is at a low level, its CZH2
domain interact is capable to with PH domain, namely as
a closed form, so Zizimin1 might be resting status for the
signaling pathway. On the other hand, in cases where
active Cdc42 is abundant, the CZH2 domain is released
from the PH domain, as a open form. The open form can
interact with Cdc42 and activate it. This information
surely lends further support to notion that Zizimin2 also
plays a physiological role for lymphocyte migration with
its PH and CZH2 domains.
Mechanism of Zizimin2 up-regulation by stimulation
We describe here Cdc42 activation and Zizimin2 up-
regulation in response to anti-Fcg receptor II/III or LPS
stimulation in BMDC (Figure 4A, B). It is worth nothing
that the response of Zizimin2 was so rapid that regula-
tion at the transcription or translation step might not be
involved in this up-regulation. Therefore, we speculate
that inhibition of Zizimin2 protein degradation is one of
the mechanisms to explain the rapid response. However,
as shown in Additional file 3: Figure S3 more Zizimin2
protein was detected in the cells stimulated with anti-
Fcg receptor II/III or LPS than the cells treated with
MG132, which is a proteasome inhibitor. Although
further analysis should be required, this result allows us
to infer that there is another mechanism to increase
Zizimin2 protein in the stimulated cells.
Zizimin2-mediated signaling pathway for lymphocyte
migration
Taken together with our present results of the signaling
pathway for filopodial formation with Zizimin2, we pro-
posed a signaling pathways for lymphocyte migration
depicted in Figure 5. In BMDC, once receiving the sig-
nals from the cognate ligands, both FcgRIII and TLR4
induce and stabilize Zizmin2 as a stable form capable to
be recruited to plasma membrane through its own PH
domain and activates Cdc42, followed by activation of
the downstream effectors, eventually it reaches to filopo-
dial formation for migration to sites pathogens infected.
As aging induces down-regulation of Zizimin2 expres-
sion, reduction of filopodial formation and migration
might be observed in aged mice.
As demonstrated in Figure 1B, Zizimin2 expression has
been observed in splenic B and T lymphocytes as well as
B M D C .T h e r e f o r e ,w ea l s os p e c u l a t et h es a m ee v e n t sa s
in BMDC regarding from TLR4 might be caused in these
lymphocytes. Since it has been reported not filopodial
but lamellipodial formation plays an important role in
migration of B cells and T cells, through Cdc42 [25,26].
Fothermore, FcgRIIB is known only FcgR which expresses
in B cells and transduces a inhibitory signal for immuno-
globulin production [27,28], this information lends
further support to speculate that FcgRIIB also transduce
a inhibitory signal against Zizimin2 regardless of TLR4
signaling. In addition to the verification of these Zizimin2
mediated signaling pathway, further understanding of
physiological function of Zizimin2 in immune system
should provide invaluable insights into improvements in
immune scenesense related to infection and immunity.
Conclusions
These data suggest that Zizimin2 is a novel immune-
system-related and age-regulated guanine nucleotide
exchange factor, which accelerates filopodial formation
through activation of Cdc42 in response to extracellular
stimulation, which leads to activation of lymphocyte
migration.
Methods
Cell culture and transfection
293T cells were grown in Dulbecco’s modified Eagle’s
Medium (DMEM, Wako Pure Chemical Industries, Osaka,
Japan) supplemented with 10% fetal bovine serum (FBS,
EQUITECH-BIO, Ingram, TX). For transfection, 293T
cells in 6-well tissue-culture plates at approximately 70%
confluence were transfected with a total of 1 μg of plasmid
vector DNA using the Fugene 6 transfection reagent
(Roche, Mannheim, Germany) according to the manufac-
turer’si n s t r u c t i o n s .
DNA constructs
Constructs described below were used for over-expres-
sion of full-length Zizimin2 or its CZH2 domain. DNA
coding full-length Zizimin2 or its CZH2 domain was
cloned into pCNX2-HA using NotI site for full-length or
EcoRI and XhoI for its CZH2 domain, which are referred
to as HA-Zizimin2 expression vector, pCNX2-HA-Zizi-
min2, and HA-CZH2 domain expression vector, pCNX2-
HA-CZH2.
Immunoblotting analysis
Tissues or cells were lysed by the addition of RIPA buffer
(25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1 mM EDTA,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) with pro-
tease inhibitors (Roche, Mannheim, Germany) and homo-
genized on ice with a homogenizer. Insoluble materials
were pelleted by centrifugation at 15,000 g for 20 min at
4°C, and protein in the supernatant was quantified by
bicinchoninic acid protein assay (Pierce, Rockford, IL).
Protein dissolved in SDS sample loading buffer (62.5 mM
Tris-HCl (pH6.8), 5% 2-mercaptoethanol, 2% SDS, 5%
sucrose, 0.002% bromophenol blue) was boiled for 5 min,
subjected to SDS-PAGE using 5-20% or 8% polyacryla-
mide gel, and transferred to polyvinylidene fluoride mem-
brane. Membrane was blocked in PBS containing 0.1%
Tween-20 (PBST) and 1% non-fat milk for Zizimin1 and
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4°C. Then, the membrane was probed for 2 h with Zizi-
min2 antibody (1:100) (214I9, [3]), Zizimin1 antibody
(1:1000) (NB500-265, Novus Biologicals, Littleton, CO),
and anti-a-tubulin antibody (1:2000) (Sigma-Aldrich, St.
Louis, MO) in PBST containing 1% non-fat milk, washed
three times with PBST, and incubated with peroxidase-
conjugated secondary antibody (1:2000) (Jackson Immu-
noResearch, West Grove, PA) for 2 h at room temperature
(RT). After several washes with PBST, reaction was visua-
lized with Immobilon Western (MILLPORE, Billerica,
MA) for detection of Zizimin2, Zizimin1, and Cdc42 or
ECL (ECL plus Western blotting Detection System, GE
Healthcare, Piscataway, NJ) for a-tubulin.
Figure 5 Schematic representation of putative lymphocyte migration pathway through Zizimin2. A) In BMDC, constitutively expressed FcgRIII
or TLR4 is activated by each ligand, resulting in the activation of Zizimin2 with the conversion from its unstable to stable form. Then the Zizimin2
interacts with plasma membrane through its own PH domain and activates Cdc42, followed by activation of the downstream effectors, consequently
induces filopodial formation for migration to sites the pathogens infected. Significantly, aging induces down-regulation of Zizimin2 expression,
resulting in reduction of filopodial formation. B) In B cells, for TLR4 signaling is cardinally active as in BMDC might be caused, except eventually
lamellipodial formation. It might be capable for FcgRIIB to transduce a inhibitory function against Zizimin2 while the signal from TLR4 comes out.
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Quantitative real-time RT-PCR was carried out as
described previously [29]. The following gene-specific
primers were used: mouse Zizimin2, 5’-TTG CCT TTT
ATG GCC AGT CT-3’ (sense) and 5’-GAG CGA ATT
TTG GAT CAA GC-3’ (antisense), mouse GAPDH, 5’-
AAT GGT GAA GGT CGG TGT G-3’ (sense) and 5’-
GAA GAT GGT GAT GGG CTT CC-3’ (antisense).
Cdc42 activation assay
For Cdc42 activation assay, we used the Cdc42 activa-
tion kit (Cytoskeleton, Denver, CO) according to the
manufacturer’s instructions.
Immunofluorescence microscopy
293T cells and BMDC cultured on poly-lysine-coated cov-
erslips were washed three times in PBS, fixed for 15 min
in 4% paraformaldehyde at 37°C, washed in PBS, and per-
meabilized with 0.1% TritonX-100 in PBS for 5 min at RT.
The coverslips were washed three times in PBS, blocked
for 1 h with 0.2% bovine serum albumin in PBS, washed
three times in PBS, and incubated for 1 h with 214I9
hybridoma culture supernatant (1:1) or 214I9 (1:100) [3]
for Zizimin2 staining, Alexa488-conjugated phalloidin
(1:500) (Invitrogen, Carlsbad, CA) for actin staining, or
sheep anti-cdc42 (1:100) (Cytoskeleton, Denver, CO) for
Cdc42 staining. Following three washes in PBS, coverslips
were incubated for 1 h with Cy3-labeled secondary antibo-
dies (Jackson ImmunoResearch, West Grove, PA), washed
three times in PBS, and mounted onto microscope slides
using Vectashield containing 4’,6-diamino-2-phenylindole
(DAPI, Vector Labs, Burlingame, CA) for nucleus detec-
tion. Images were acquired using a Fluoview laser scan-
ning microscope (OLYMPUS, Tokyo, Japan).
Isolation of BMDC, pDC, and mDC
Bone marrow cells obtained from C57/BL6 mouse were
maintained in RPMI1640 supplemented with 10% X63-
GM cell culture supernatants as a source of granulocyte
macrophage colony-stimulating factor (GM-CSF) or
50 ng/ml FMS-like tyrosine kinase 3 (Flt3) (R&D SYS-
TEMS, Minneapolis, MN) for 6 days to induce BMDC.
On the 6th day, the cells were stimulated with 1 μg/ml
lipopolysaccharide (LPS) and cultured for 2 more days. On
the 8th day, the cells were stained with FITC-conjugated
anti-CD11c antibody (BD Bioscience, Franklin Lakes, NJ)
and CD11c-positive cells were sorted using a cell sorter,
JSAN (Bay Bioscience, Kobe, Japan), which were defined
as BMDC in this study. pDC (CD11c
+,B 2 2 0
+,m P D C A - 1
+,
Ly-6C
+)a n dm D C( C D 1 1 c
+,B 2 2 0
-)w e r es o r t e df r o m
BMDC using a cell sorter, JSAN (Bay Bioscience, Kobe,
Japan). All animal procedures were approved by institu-
tional reviews board at National Center for Geriatrics and
Gerontology followed the guideline issued by Japanese
Ministry of Health Labour and Welfare.
Isolation of B cells and T cells
Splenocyte suspension was prepared from mouse spleen
and splenic B cells or T cells were isolated with MACS
beads (Miltenyi Biotec, Gladbach, Germany), according
to the manufacturer’s instructions.
Additional material
Additional file 1: Figure S1. Equal amount of protein loaded to the gel.
The proteins on the membrane were stained with pomso.
Additional file 2: Figure S2. Over-expression of Cdc42 induced
filopodial formation. 293T cells transfected with empty vector, or
expression vectors with Cdc42WT, Cdc42V12, or Cdc42N17 were stained
with phalloidin (left panel) and anti-Cdc42 antibody (middle panel)
followed by immunofluorescence microscopy. Right panels are merged
images of phalloidin-stained and anti-Cdc42-stained images. White bars
are 10 μm.
Additional file 3: Figure S3. Inhibition of degradation partially involved
in up-regulation of Zizimin2 in response to stimulation. 10
7cells/ml of
BMDC with 1 h treatment of 10 μM MG132 or without the treatment
that were stimulated with 1 μg/ml anti-IgG Fab’2 for 2 min (left panel,
anti-FcgRII/III) or 1 μg/ml LPS for 5 min (right panel) were lysed and
subjected to western blotting. a-Tubulin was used as a loading control.
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